Cite
Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.
MLA
Nakamae, Hirohisa, et al. “Dasatinib versus Imatinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Subanalysis of the DASISION 5-Year Final Report.” International Journal of Hematology, vol. 105, no. 6, June 2017, pp. 792–804. EBSCOhost, https://doi.org/10.1007/s12185-017-2208-2.
APA
Nakamae, H., Fujisawa, S., Ogura, M., Uchida, T., Onishi, Y., Taniwaki, M., Utsunomiya, A., Matsue, K., Takamatsu, Y., Usuki, K., Tanimoto, M., Ishida, Y., Ohashi, K., Li, L., & Miyoshi, M. (2017). Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. International Journal of Hematology, 105(6), 792–804. https://doi.org/10.1007/s12185-017-2208-2
Chicago
Nakamae, Hirohisa, Shin Fujisawa, Michinori Ogura, Toshiki Uchida, Yasushi Onishi, Masafumi Taniwaki, Atae Utsunomiya, et al. 2017. “Dasatinib versus Imatinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Subanalysis of the DASISION 5-Year Final Report.” International Journal of Hematology 105 (6): 792–804. doi:10.1007/s12185-017-2208-2.